TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03601793

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alcohol Help Center
Description: An internet intervention based on CBT consisting of about 20 modules aimed at helping people with drinking problems
Study: NCT02124941

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 1H MRS
Description: All subjects will undergo three magnetic resonance spectroscopy (1H-MRS) scans at 7T, including before and after two-weeks of placebo and NAC administration.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [11C]APP311 PET scan
Description: All subjects will undergo \[11C\]APP311 PET imaging to investigate whether there are differences in synaptic integrity / neuronal plasticity in the brains of individuals abstinent from cocaine compared to healthy controls at baseline.
Study: NCT00003851

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: proteolytic enzymes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine hydrochloride
Study: NCT02173405

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OnabotulinumtoxinA
Description: comparison of OnabotulinumtoxinA with placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: comparison of placebo with investigational drug OnabotulinumtoxinA
Study: NCT00042289

Intervention type: DRUG
Intervention: efavirenz
Description: efavirenz 600 mg q.d.

Intervention type: DRUG
Intervention: darunavir/cobicistat
Description: darunavir/cobicistat 800/150 mg q.d.
Study: NCT03601793

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol Help Center
Description: An internet intervention based on CBT consisting of about 20 modules aimed at helping people with drinking problems

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assistance from a health educator
Description: This entails email contact with a health educator that guides the participant through the Alcohol Help Center during the first two weeks
Study: NCT04020406

Intervention type: BIOLOGICAL
Intervention: Antibacterial Activity
Description: Antibacterial Activity of Urea Solution against Ocular Bacterial Isolates
Study: NCT00702728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide and matched saline hydration
Description: Subjects will begin treatment approximately 90 minutes prior to the start of catheterization procedure. After a pre-hydration bolus of 250 ml of normal saline solution over 30 minutes the patient will receive 0.5 mg/kg of furosemide intravenously. Then, a replacement solution (saline) is given in an amount matched (ml for ml) to the volume of urine produced. Matched hydration will occur prior, during, and 4 hours post procedure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: isotonic saline solution
Description: Subjects will receive 1 ml/Kg/hr of intravenous saline solution for a minimum of 12 hours prior to catheterization. Hydration will continue to occur during the catheterization, and for a minimum of 12 hours post catheterization.
Study: NCT01248364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Description: BI 10773 tablets once daily high dose
Study: NCT04140604

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lactobacillus salivarius AP-32
Description: Infants will be given the content of one capsule (mixed in infant formula or breast milk) twice daily (morning and evening) for 15 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bifidobacterium animalis subsp. lactis CP-9
Description: Infants will be given the content of one capsule (mixed in infant formula or breast milk) twice daily (morning and evening) for 15 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Infants will be given the content of one capsule (mixed in infant formula or breast milk) twice daily (morning and evening) for 15 weeks.
Study: NCT02418767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOD-4023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOD-4023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOD-4023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT01126502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alvespimycin hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diagnostic laboratory biomarker analysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacogenomic studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Study: NCT01652937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB057
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB057
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB057
Description: Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral
Study: NCT03228498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Choline alphoscerate
Description: Choline alphoscerate 600 mg b.i.d plus Nimodipine 30 mg t.i.d

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo b.i.d plus Nimodipine 30 mg t.i.d
Study: NCT00042289

Intervention type: DRUG
Intervention: darunavir/cobicistat
Description: darunavir/cobicistat 800/150 mg q.d.
Study: NCT02762799

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Leucostim®
Description: Leucostim® is filgrastim biosimilar.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Leucostim®
Description: Leucostim® is filgrastim biosimilar.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Leucostim®
Description: Leucostim® is filgrastim biosimilar.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Leucostim®
Description: Leucostim® is filgrastim biosimilar.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neupogen®
Study: NCT02762799

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neupogen®

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neupogen®

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neupogen®
Study: NCT05281848

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgical periodontal treatment
Description: Non-surgical periodontal treatment includes periodontal prophylaxis and root planning. No other methods or any of drugs will be used.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgical periodontal treatment
Description: Non-surgical periodontal treatment includes periodontal prophylaxis and root planning. No other methods or any of drugs will be used.
Study: NCT01329289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOM230
Description: 60 mg intramuscularly (IM) on day 1 of each 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: 1.3 mg/m2 intravenously (IV) on days 1, 4, 8, and 11 of each cycle. Bortezomib will be infused by IV push.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 20 mg orally on day of and day after bortezomib (Days 1, 2, 4, 5, 8, 9, 11, 12).
Study: NCT02700919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCT197
Description: Capsules will be taken orally with fluids over a 5 day period after randomization

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCT197
Description: Capsules will be taken orally with fluids over a 5 day period after randomization

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules will be taken orally with fluids over a 5 day period after randomization
Study: NCT01570933

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NivNava
Description: Non-invasive Nava ventilation mode on nasal cannula

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cpap
Description: nasal Cpap on nasal cannula
Study: NCT03141892

Intervention type: DEVICE
Intervention: FreeStyle Libre Flash Glucose Monitoring System
Description: Blood Glucose Monitoring
Study: NCT03994536

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A Person-Centred Transition Program to Empower Adolescents With Type 1 Diabetes in the Transition to Adulthood: the STEPSTONES-DIAB Project
Description: Behavioral: Transition program Participants will be part of a transition program that aim to prepare them for adult life and adult care wich includes eight key components: 1. A transition coordinator; 2. Education on diabetes, treatments, health behavior, dealing with school, friends; 3. Telephone availability; 4. Information about the adult diabetes service: 5. Guidance of parents; 6. Meeting with peers: 7. A person-centered transition plan; and 8. Preparation and transfer to adult diabetes service.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard care
Description: Participants allocated to this group will receive usual care, which includes regular follow-up visits in pediatric diabetes outpatient clinics. Usual care can vary across the two clinics, however, they all include meetings with a nurse and a physician.
Study: NCT00978679

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthokeratology lenses
Description: Nightly use of orthokeratology lenses to correct the refractive errors

Intervention type: DEVICE
Group type: OTHER
Intervention: Spectacles
Description: Daily use of single vision lenses to correct refractive errors
Study: NCT01305304

Intervention type: OTHER
Intervention: repeated long term endurance exercise
Description: competitive running at a national level during a period of at least 5 years (i.e. approximately 50km per week over more than 10 years)

Intervention type: OTHER
Intervention: Other
Description: No history of endurance sports activity
Study: NCT03824535

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT
Study: NCT00042289

Intervention type: DRUG
Intervention: lopinavir/ritonavir dosage #1
Description: lopinavir/ritonavir 800/200mg b.i.d.

Intervention type: DRUG
Intervention: atazanavir/ritonavir/tenofovir dosage #1
Description: atazanavir/ritonavir/tenofovir 300/100/300mg q.d.
Study: NCT03824535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorine F 18 L-glutamate Derivative BAY94-9392
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study: NCT00042289

Intervention type: DRUG
Intervention: atazanavir/ritonavir/tenofovir dosage #1
Description: atazanavir/ritonavir/tenofovir 300/100/300mg q.d.

Intervention type: DRUG
Intervention: atazanavir/ritonavir/tenofovir dosage #1
Description: atazanavir/ritonavir/tenofovir 300/100/300mg q.d.

Intervention type: DRUG
Intervention: atazanavir/ritonavir/tenofovir dosage #1
Description: atazanavir/ritonavir/tenofovir 300/100/300mg q.d.

Intervention type: DRUG
Intervention: rifampicin
Description: rifampicin 8-12 mg/kg (max 600 mg) q.d.; 8-12 mg/kg (max 900 mg) t.i.w.
Study: NCT01206829

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 8-session CBTcourse
Description: Hearing impaired workers voluntarily sign up for an 8 session cognitive therapy course. The study has a waiting list control group design. Participants will be randomized assigned to either an experiment group that will be offered to start on an immediate course, or a control group that will be offered the same course 12 months later.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 8 session cognitive behavioral therapy
Description: 8 sessions cognitive behavioral therapy in group
Study: NCT03293303

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stay Active at Home
Description: Stay Active at Home' aims to change the behaviour of community nurses and domestic support workers by offering them an intensive training programme. Subsequently, professionals are expected to deliver goal-oriented, holistic and person-centred services focusing on supporting older adults to maintain, gain or restore their competences to engage in physical and daily activities so that they can manage their everyday life as independently as possible.
Study: NCT02879513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluoruracil
Study: NCT00066690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Exemestane 25mg orally daily for 5 years plus ovarian function suppression

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oophorectomy
Description: Undergo bilateral surgical oophorectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oophorectomy
Description: Undergo bilateral surgical oophorectomy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo ovarian irradiation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo ovarian irradiation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Tamoxifen 20mg orally daily for 5 years

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Description: Tamoxifen 20mg orally daily for 5 years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin
Description: 3.75 mg by im injection q28 days for 5 years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin
Description: 3.75 mg by im injection q28 days for 5 years
Study: NCT01774773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group A: E5501 5mg, then 20mg, then 40 mg, then 5mg
Description: The post-randomization phase consists of the Treatment Period 1 (Visits 2-8): participants received one 5 mg tablet under fed conditions on treatment morning for 28 days. Treatment Period II (visits 9-15): 20 mg (four 5 mg tablets) under fed conditions on treatment morning for 28 days. Treatment Period III (visits 16-22): 40 mg (eight 5 mg tablets) under fed conditions on treatment morning for 28 days.~Treatment Period IV (visits 23-29): 5 mg tablet on treatment morning under fasted conditions for 28 days.~The washout period of 27 days or longer was set between the administration of the study drug in Treatment Periods 1, 2 and 3 and that in Treatment Periods 2, 3 and 4 respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group B: E5501 20mg, then 40mg, then 5 mg, then 5mg
Description: The post-randomization phase consists of the Treatment Period 1 (Visits 2-8): participants received 20 mg (four 5 mg tablets) under fed conditions on treatment morning for 28 days. Treatment Period II (visits 9-15): 40 mg (eight 5 mg tablets) under fed conditions on treatment morning for 28 days. Treatment Period III (visits 16-22): one 5 mg tablet under fed conditions on treatment morning for 28 days.~Treatment Period IV (visits 23-29): 5 mg tablet on treatment morning under fasted conditions for 28 days.~The washout period of 27 days or longer was set between the administration of the study drug in Treatment Periods 1, 2 and 3 and that in Treatment Periods 2, 3 and 4 respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group C: E5501 40mg, then 5mg, then 20 mg, then 5mg
Description: The post-randomization phase consists of the Treatment Period 1 (Visits 2-8): participants received 40 mg (eight 5 mg tablets) under fed conditions on treatment morning for 28 days. Treatment Period II (visits 9-15): one 5 mg tablet under fed conditions on treatment morning for 28 days. Treatment Period III (visits 16-22): 20 mg (four 5 mg tablets) under fed conditions on treatment morning for 28 days.~Treatment Period IV (visits 23-29): 5 mg tablet on treatment morning under fasted conditions for 28 days.~The washout period of 27 days or longer was set between the administration of the study drug in Treatment Periods 1, 2 and 3 and that in Treatment Periods 2, 3 and 4 respectively.
Study: NCT02547103

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate-soaked cloths

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mupirocin ointment
Study: NCT00125970

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVDNA016-00-VP
Description: 4 mg administered in deltoid

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVADV014-00-VP
Description: 1 x 10\^10 PU administered in deltoid

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: VRC-HIVDNA016-00-VP placebo
Description: 1 mL administered at study entry and Months 1 and 2
Study: NCT02482012

Intervention type: OTHER
Intervention: Survey
Description: This was a survey

Intervention type: OTHER
Intervention: Survey
Description: This was a survey
Study: NCT00125970

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: VRC-HIVADV014-00-VP placebo
Description: 1 mL administered at Month 6
Study: NCT00941525

Intervention type: DRUG
Group type: OTHER
Intervention: Latanoprost
Description: 1 eyedrop of latanoprost (0.005%) dosed once a day at 8:00pm for a 4-weeks period
Study: NCT04288856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB078
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB078
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB078
Description: Administered as specified in the treatment arm.
Study: NCT00042289

Intervention type: DRUG
Intervention: rifampicin
Description: rifampicin 8-12 mg/kg (max 600 mg) q.d.; 8-12 mg/kg (max 900 mg) t.i.w.

Intervention type: DRUG
Intervention: rifampicin
Description: rifampicin 8-12 mg/kg (max 600 mg) q.d.; 8-12 mg/kg (max 900 mg) t.i.w.

Intervention type: DRUG
Intervention: ethambutol
Description: ethambutol 15-20 mg/kg q.d., 25-35 mg/kg t.i.w.

Intervention type: DRUG
Intervention: ethambutol
Description: ethambutol 15-20 mg/kg q.d., 25-35 mg/kg t.i.w.
Study: NCT05130372

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Static Stretching Method Group
Description: Static stretching has been the most common stretching method applied to the ankle in healthy older adults, and different protocols have proven to increase ankle range of motion. In this study, the static stretching method was actively applied while standing.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PNF Stretching Method Group
Description: The contract-relax technique was used in the PNF stretching method.
Study: NCT00042289

Intervention type: DRUG
Intervention: ethambutol
Description: ethambutol 15-20 mg/kg q.d., 25-35 mg/kg t.i.w.

Intervention type: DRUG
Intervention: ethambutol
Description: ethambutol 15-20 mg/kg q.d., 25-35 mg/kg t.i.w.

Intervention type: DRUG
Intervention: isoniazid
Description: isoniazid 4-6 mg/kg (max 300 mg) q.d.; 8-12 mg/kg (max 900 mg) t.i.w.
Study: NCT04288856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB078
Description: Administered as specified in the treatment arm.
Study: NCT02905279

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Biofeedback Relaxation Training
Description: Participants will receive one-session biofeedback relaxation training (24 minutes) for anxiety reduction. Prior to biofeedback, participants will receive education about spiders and the development and maintenance of spider phobia.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure Therapy
Description: Participants will receive one-session exposure therapy (24 minutes) for fear of spiders. Prior to exposure therapy, participants will receive education about spiders and the development and the development and maintenance of spider phobia.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure with Threat-Relevant Opposite Actions
Description: Participants will receive one-session exposure therapy (24 minutes) for fear of spiders. During exposure, participants will engage in actions opposite to the tendencies associated with threat avoidance. Prior to exposure therapy, participants will receive education about spiders and the development and maintenance of spider phobia.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure with Threat-Irrelevant Opposite Actions
Description: Participants will receive one-session exposure therapy (24 minutes) for fear of spiders. During exposure therapy, participants will engage in actions opposite of the action tendencies associated with the fear, but unrelated to the specific threats associated with spider phobia. Prior to exposure therapy, participants will receive education about spiders and the development and maintenance of spider phobia.
Study: NCT05067881

Intervention type: PROCEDURE
Intervention: Pulmonary resection
Description: Resection of pneumohematocele
Study: NCT03048201

Intervention type: DEVICE
Group type: OTHER
Intervention: Physica Kinematic Retaining Knee System
Description: Modular total knee prosthesis with a Kinematic Retaining mechanism and posterior cruciate ligament (PCL) preservation

Intervention type: DEVICE
Group type: OTHER
Intervention: Physica Cruciate Retaining Knee System
Description: Total knee prosthesis with posterior cruciate ligament (PCL) preservation

Intervention type: DEVICE
Group type: OTHER
Intervention: Physica Posterior Stabilized Knee System
Description: Total knee prosthesis that sacrifices the posterior cruciate ligament (PCL) and replaces the functionality of the PCL with a post-cam mechanism.

Intervention type: DEVICE
Group type: OTHER
Intervention: Physica Cruciate Retaining Knee System with LMC Liner
Description: Total knee prosthesis with posterior cruciate ligament (PCL) preservation